{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:21:06Z","timestamp":1764746466161,"version":"3.46.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Shanghai Jiao Tong University School of Medicine Double Hundred Plan","award":["20172005"],"award-info":[{"award-number":["20172005"]}]},{"DOI":"10.13039\/501100008233","name":"Shanghai Jiao Tong University School of Medicine","doi-asserted-by":"publisher","award":["RJKH(P)-2024-026"],"award-info":[{"award-number":["RJKH(P)-2024-026"]}],"id":[{"id":"10.13039\/501100008233","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Jiao Tong University School of Nursing"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Clinical trials have shown promising clinical and safety outcomes of neoadjuvant chemoradiotherapy combined with immunotherapy (nICRT) in patients with resectable oesophageal cancer. However, knowledge of the impact of nICRT on symptomatic improvement and quality of life (QOL) remains scarce. Therefore, this study compared postoperative patient-reported outcomes in patients with oesophageal cancer receiving nICRT and those receiving neoadjuvant chemoradiotherapy alone (nCRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Among 92 patients, 25 were selected from each group after propensity score matching. Repeated-measures analysis of variance was used to assess differences in QOL, symptoms, anxiety, and depression using the M.D. Anderson Symptom Inventory, Quality of Life Questionnaire Core 30, and Hospital Anxiety and Depression Scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, no significant differences were observed in overall health status or functional scores (P\u2009&amp;gt;\u2009.05). However, the nICRT group reported better nausea, vomiting, and pain scores (P\u2009&amp;lt;\u2009.05). Over time, both groups showed significant improvements in overall health (F\u2009=\u20095.222, P\u2009&amp;lt;\u2009.01) and functional subscale scores (physical, role, emotional, and cognitive; all P\u2009&amp;lt;\u2009.001). The nICRT group demonstrated significantly better pain, fatigue, nausea, and vomiting scores (P\u2009&amp;lt;\u2009.05). Anxiety and depression improved significantly in both groups (P\u2009&amp;lt;\u2009.001), with greater anxiety reduction in the nICRT group (P\u2009&amp;lt;\u2009.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The nICRT group exhibited better QOL, fewer adverse symptoms, and lower anxiety and depression levels postoperatively, suggesting that nICRT may enhance recovery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejcts\/ezaf414","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T12:53:45Z","timestamp":1763211225000},"source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Radio-Chemo-Immunotherapy Impact on Postoperative Patient-Reported Outcomes in Oesophageal Cancer"],"prefix":"10.1093","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1351-7622","authenticated-orcid":false,"given":"Yanxia","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-7557","authenticated-orcid":false,"given":"Yuqin","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolong","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Nursing, Shanghai Jiao Tong University , Shanghai 200025,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nursing, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nursing, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8069-6033","authenticated-orcid":false,"given":"Hecheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2025120302170239100_ezaf414-B1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025120302170239100_ezaf414-B2","first-page":"221","article-title":"Cancer incidence and mortality in China, 2022","volume":"46","author":"Zheng","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"2025120302170239100_ezaf414-B3","doi-asserted-by":"crossref","first-page":"e2239778","DOI":"10.1001\/jamanetworkopen.2022.39778","article-title":"Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis","volume":"5","author":"Ge","year":"2022","journal-title":"JAMA Netw Open."},{"key":"2025120302170239100_ezaf414-B4","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3748\/wjg.v30.i19.2496","article-title":"Immunotherapy for esophageal cancer: where are we now and where can we go","volume":"30","author":"Shoji","year":"2024","journal-title":"World J Gastroenterol"},{"key":"2025120302170239100_ezaf414-B5","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025120302170239100_ezaf414-B6","doi-asserted-by":"crossref","first-page":"103729","DOI":"10.1016\/j.critrevonc.2022.103729","article-title":"The immune response to major gastrointestinal cancer surgery and potential implications for adjuvant immunotherapy","volume":"175","author":"Donlon","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025120302170239100_ezaf414-B7","doi-asserted-by":"crossref","first-page":"e10875","DOI":"10.2196\/10875","article-title":"Electronic systems for patients to report and manage side effects of cancer treatment: systematic review","volume":"21","author":"Warrington","year":"2019","journal-title":"J Med Internet Res"},{"key":"2025120302170239100_ezaf414-B8","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","article-title":"EORTC qualify of life group; quality of life unit. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur J Cancer"},{"key":"2025120302170239100_ezaf414-B9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/gut.49.2.227","article-title":"The prognostic value of quality of life scores during treatment for oesophageal cancer","volume":"49","author":"Blazeby","year":"2001","journal-title":"Gut"},{"key":"2025120302170239100_ezaf414-B10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtho.2016.10.016","article-title":"Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer","volume":"12","author":"Rice","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2025120302170239100_ezaf414-B11","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/cncr.20448","article-title":"Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients","volume":"101","author":"Wang","year":"2004","journal-title":"Cancer"},{"key":"2025120302170239100_ezaf414-B12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0895-4356(96)00428-3","article-title":"Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement","volume":"50","author":"Groenvold","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"2025120302170239100_ezaf414-B13","first-page":"3921","article-title":"Hospital Anxiety and Depression Scale (HADS) accuracy in cancer patients","volume":"28","author":"Annunziata","year":"2020","journal-title":"Support Care Cancer"},{"key":"2025120302170239100_ezaf414-B14","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"key":"2025120302170239100_ezaf414-B15","doi-asserted-by":"crossref","first-page":"1108213","DOI":"10.3389\/fimmu.2023.1108213","article-title":"Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: a systematic review and meta-analysis","volume":"14","author":"Qin","year":"2023","journal-title":"Front Immunol"},{"key":"2025120302170239100_ezaf414-B16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ejso.2021.08.015","article-title":"Impact of curative treatment on the physical fitness of patients with esophageal cancer: a systematic review and meta-analysis","volume":"48","author":"Reijneveld","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"2025120302170239100_ezaf414-B17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025120302170239100_ezaf414-B18","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"2025120302170239100_ezaf414-B19","doi-asserted-by":"crossref","first-page":"e1324","DOI":"10.1093\/oncolo\/oyae087","article-title":"Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer","volume":"29","author":"Mansoor","year":"2024","journal-title":"Oncologist"},{"key":"2025120302170239100_ezaf414-B20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/JCO.21.00601","article-title":"Impact of pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer on Health-Related quality of life in KEYNOTE-181","volume":"40","author":"Adenis","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025120302170239100_ezaf414-B21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025120302170239100_ezaf414-B22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025120302170239100_ezaf414-B23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2025120302170239100_ezaf414-B24","doi-asserted-by":"crossref","first-page":"113601","DOI":"10.1016\/j.ejca.2024.113601","article-title":"Real-world health-related quality of life outcomes for patients with resected stage III\/IV melanoma treated with adjuvant anti-PD1 therapy","volume":"200","author":"Egeler","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025120302170239100_ezaf414-B25","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1245\/s10434-022-11629-7","article-title":"Establishment of minimal clinically important improvement for Patient-Reported symptoms to define recovery after Video-Assisted thoracoscopic surgery","volume":"29","author":"Xu","year":"2022","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejcts\/advance-article-pdf\/doi\/10.1093\/ejcts\/ezaf414\/65355989\/ezaf414.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/67\/12\/ezaf414\/65355989\/ezaf414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/67\/12\/ezaf414\/65355989\/ezaf414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:17:13Z","timestamp":1764746233000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article\/doi\/10.1093\/ejcts\/ezaf414\/8325119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezaf414","relation":{},"ISSN":["1010-7940","1873-734X"],"issn-type":[{"type":"print","value":"1010-7940"},{"type":"electronic","value":"1873-734X"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,17]]},"article-number":"ezaf414"}}